抄録
Investigation was made on anemia in leprosy, especially its relationship with the antileprosy drugs.
1. In comparison with healthy individuals, leprosy patients without any treatment show slightly lower erythrocyte count and hemoglobin content, however no change is seen among hemoglobin index. Anemia is observed more frequently on lepromatous type patients than tuberculoid type patients.
2. With the administration of antileprosy drugs among the leprosy patients anemia (diminishing of erythrocyte count less than 500, 000 or hemoglobin content less than 10%) appears in 33-60% by Promin or DDS and in 8% by Ciba 1906. The erythrocyte count is 1, 000, 000 in average and that of the hemoglobin content is around 18%.
3. Except a fairly high rate of the appearance of anemia followed the administration of Promin and DDS, no remarkable difference was observed among other cases treated by the antileprosy drugs such as Promizol, Diazon, Ciba 1906 and Taifumin.
4. The number of Promin injections has almost no relation to the frequency of the appearance of anemia, but in the cases that the injections were repeated more than 1, 600 times during the period of 10 years, there was a slight elevation in the frequency. Dose of a single injection or sex of the cases have no influence on the frequency of appearance of anemia.
5. Anemia caused by the sulfone drugs administration is considered to be due to the lowering of the bone marrow functions.
6. Anemia of leprosy is alleviated by the use of antileprosy drugs.
7. Liver preparations and vitamin B12 are effective for the treatment of the anemia caused by the administration of antileprosy drugs.
